Clinical Trial Update: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Janus kinase inhibitors to preserve C-peptide production in individuals with new-onset Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Janus Kinase Inhibitors

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: ACTIVE_NOT_RECRUITING